MSX Pre-IPO Fund III Places Dual Bets on Neuralink and Anduril: From Human Brain to Battlefield"

"article":"The data is unusual. A Pre-IPO fund has simultaneously acquired stakes in Neuralink and Anduril, two companies that represent the most extreme poles of artificial intelligence application: biological integration and autonomous warfare. This is not a portfolio strategy. It is a structural thesis on where alpha will migrate over the next decade. \n\nThe announcement from MSX's Pre-IPO Fund III has been circulating in private market circles, and the logic is straightforward: enter before the IPO, exit at the public listing, target a 3-5x multiple. But beneath the simple capital flow lies a more significant signal. Both companies are at critical inflection points, and the timing of this entry suggests the fund is betting not on narratives, but on technical milestones that are already documented. Alpha isn't extracted from the noise floor. It is located in the gap between public perception and technical reality.\n\n## Context: Two Companies, Two Timelines\n\nNeuralink's technology roadmap is now at the transition from proof-of-concept to production. The company completed its first human implantation in January 2024 with the N1 chip, a 1,024-channel invasive brain-computer interface. The second patient was implanted in August 2024. By 2025, the FDA granted breakthrough device designation, and three patients are currently implanted. The technical architecture uses flexible threads approximately one-quarter the thickness of a human hair, inserted by the R1 surgical robot, which is designed to avoid vascular structures during implantation. In November 2025, Neuralink received FDA approval to launch the CONVOY feasibility study, connecting the N1 chip to assistive robotic arms to explore neural control of prosthetics in paralyzed patients.\n\nThe core technical balancing act is high-bandwidth neural signal acquisition versus surgical invasiveness. This is not a software problem. It is a hardware and biological safety problem.\n\nAnduril, by contrast, has already moved into scaled production. Its Lattice software platform integrates AI-driven sensor fusion and autonomous decision-making across heterogeneous hardware systems, including the Anvil counter-drone system, the Dive-LD autonomous submersible, and the Roadrunner missile system. In June 2025, the company announced a strategic partnership with OpenAI to develop counter-unmanned aerial systems (C-UAS) for US and allied military bases. In December 2025, Anduril agreed to acquire UK-based 3D printing drone company Callum for between 1.3 and 1.4 billion dollars. The company's 2025 revenue is projected at approximately 1 billion dollars, a year-over-year increase of around 150%.\n\nThe technology stack is a software-defined defense architecture that closes the loop between sensing, decision, and response.\n\n## Core Analysis: Divergent Trajectories, Convergent Thesis\n\nMy analysis of these two companies is based on observable milestones, not narratives.\n\nNeuralink's valuation history is instructive. In 2023, the company raised at approximately 5 billion dollars. Market expectations for the current funding round place the valuation at 8-10 billion dollars, driven by Pre-IPO demand. The company has essentially zero revenue, and the price-to-sales ratio is infinite. The price-to-R&D ratio, however, is the more relevant metric, which I estimate at 50-100x based on roughly 100 million dollars in annual R&D spend. This is a speculative valuation, but it is not irrational if you accept the premise that a fully approved brain-computer interface in the US market has the potential to address a patient population of significant scale, and the total addressable market for the technology is expanding.\n\nAnduril's valuation basis is more tangible. The current private market valuation is around 14 billion dollars, with recent rounds potentially reaching 25-30 billion dollars. The forward price-to-sales ratio is 14-28x, based on projected revenue of 10 billion dollars. This is cheaper than Palantir's 30-50x, but the growth rate justifies the premium. The company's revenue growth of 150 percent is backed by a 250 million dollar contract from the Defense Innovation Unit for a large-scale expeditionary combat system, plus an additional contract with the UK Ministry of Defense to supply counter-drone systems to Ukraine.\n\nIt is the combination of these two assets that forms the true thesis. One company is building the interface between the human brain and digital machines. The other is building autonomous systems that operate without human intervention in physical environments. The apparent contradiction is a structural complement: both are betting on the same trend, which is the extension of AI from digital space into biological and physical reality.\n\nBased on my audit experience, the technical risks are more transparent than the market narrative suggests. Neural is not just facing a technical challenge, but a regulatory one. FDA approval is conditional, and the company must continue to submit safety data. A serious adverse event, such as infection or electrode failure, would delay commercialization and potentially cause a 50 percent downward revaluation. And the company is not the only player in the BCI space; Synchron has 16 channels in its Stentrode device and has implanted 10 patients, with less invasive technology that has regulatory advantages. Precision Neuroscience has a micro-electrode array with 30 patients, and Paradromics is also developing high-channel-count systems.\n\nThe competitive landscape suggests a fork in the road: Neuralink's high bandwidth could be displaced by non-invasive alternatives that are safer and easier to approve.\n\nAnduril's defense contracts are subject to a different type of risk. The U.S. Department of Defense is the primary buyer, and concentration risk is high. Hardware manufacturing capability is still being validated. The company faces competition from traditional defense contractors Lockheed Martin and RTX, which are deploying their own AI transformation programs, as well as Palantir's decision platform, which has deeper relationships with government agencies.\n\n## Contrarian View: The Retail Blind Spot\n\nRetail market participants continue to price these companies based on narrative momentum. The AI narrative premium is built into both valuations, but the market is not pricing in the execution gap between the two companies. Neuralink's timeline for FDA approval is a 2026-2027 window at best, and the company is unlikely to have meaningful revenue before that. And the company is also on a longer timeline, with consumer applications such as memory enhancement and human-computer interaction not expected before 2030.\n\nAnduril, on the other hand, is already generating revenue and is on a path to break even by 2026 and be profitable by 2027.\n\nThe asymmetry is the key insight. Both companies are in the same fund, but they are at different stages of the capital cycle. Neuralink is still a science experiment with a high probability of failure. Anduril is a business with a government contract and a clear path to revenue. The MSX fund is effectively combining one high-risk, high-reward bet with one near-term revenue growth story.\n\nThe market is pricing them as if they are the same type of asset. They are not.\n\n## Risk Assessment\n\nEthical and safety considerations are part of the risk assessment, not a separate category. Neuralink's invasive approach raises issues of autonomy, privacy, and identity. The data collected by the BCI is the most sensitive form of personal data. If compromised, the consequences are not financial but exist in the realm of personal autonomy. Anduril's autonomous weapons systems raise concerns about lethal autonomous weapons (LAWS), and the international regulatory framework is still under discussion. There is no consensus on the use of autonomous weapons in conflict.\n\nThese risks are not abstract. They are embedded in the regulatory pathways that both companies must navigate. The EU AI Act and the US AI Executive Order are still evolving. If the regulatory framework changes, the market size for both companies will change accordingly.\n\n## Takeaway\n\nVolatility is just liquidity waiting to be reborn. The capital that is moving into Pre-IPO funds now is anticipating the next cycle of liquidity. The MSX bet is not about the two companies; it is about the belief that the next decade will be defined by the intersection of AI, biology, and hardware. The question is not whether these two companies will survive, but whether they can deliver on their technical milestones in the expected timeframe. In a market where narrative is no longer a substitute for execution, the answer will be determined by data. The next 12 months will provide the first test of that thesis.